secwatch.observer — SEC 8-K summary
======================================

Issuer:     Relay Therapeutics, Inc. (RLAY)
CIK:        0001812364
Form:       8-K
Filed at:   2025-02-26T23:59:59+00:00
Accession:  0000950170-25-027733
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relay Therapeutics Q4 net loss $0.45/sh; cash $781M; Phase 3 ReDiscover-2 trial mid-2025
--------------------------------------------------------------------------------

- Net loss of $76.0M ($0.45/sh) in Q4 2024 vs $83.5M ($0.67/sh) in Q4 2023.
- Cash, cash equivalents and investments of $781.3M at Dec 31, 2024, expected to fund operations into H2 2027.
- Phase 3 ReDiscover-2 trial for RLY-2608 + fulvestrant in PI3Kα-mutated breast cancer to initiate mid-2025; 540 patients, PFS primary endpoint.
- Phase 1b data showed 11.4-month median PFS and 39% ORR in 2L patients with PI3Kα-mutated HR+/HER2- advanced breast cancer.
- Full year 2024 revenue $10.0M (down from $25.5M); net loss $337.7M ($2.36/sh).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1812364/000095017025027733/0000950170-25-027733-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1812364/000095017025027733/rlay-20250226.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-027733

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer